<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-US">
	<id>https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3ACapital_adequacy_%28M%26A%29</id>
	<title>Definition:Capital adequacy (M&amp;A) - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://www.insurerbrain.com/w/index.php?action=history&amp;feed=atom&amp;title=Definition%3ACapital_adequacy_%28M%26A%29"/>
	<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Capital_adequacy_(M%26A)&amp;action=history"/>
	<updated>2026-05-04T23:32:50Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.8</generator>
	<entry>
		<id>https://www.insurerbrain.com/w/index.php?title=Definition:Capital_adequacy_(M%26A)&amp;diff=10191&amp;oldid=prev</id>
		<title>PlumBot: Bot: Creating new article from JSON</title>
		<link rel="alternate" type="text/html" href="https://www.insurerbrain.com/w/index.php?title=Definition:Capital_adequacy_(M%26A)&amp;diff=10191&amp;oldid=prev"/>
		<updated>2026-03-11T07:00:59Z</updated>

		<summary type="html">&lt;p&gt;Bot: Creating new article from JSON&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;🏦 &amp;#039;&amp;#039;&amp;#039;Capital adequacy (M&amp;amp;A)&amp;#039;&amp;#039;&amp;#039; refers to the assessment of whether an [[Definition:Insurance carrier | insurance company]] or combined entity will maintain sufficient capital — above regulatory minimums and at levels consistent with operational needs — following the completion of a [[Definition:Insurance mergers and acquisitions (M&amp;amp;A) | merger, acquisition]], or related restructuring. In insurance, capital is not merely a financial cushion; it is the regulatory currency that enables an insurer to write [[Definition:Premium | premium]], honor [[Definition:Claims | claims]], and maintain [[Definition:License (insurance) | licenses]] across jurisdictions. An M&amp;amp;A transaction that consumes too much capital, loads excessive [[Definition:Goodwill | goodwill]] onto the balance sheet, or introduces unfunded [[Definition:Loss reserves | reserve liabilities]] can push the combined entity below [[Definition:Risk-based capital (RBC) | risk-based capital (RBC)]] thresholds and invite immediate [[Definition:Regulatory action | regulatory intervention]].&lt;br /&gt;
&lt;br /&gt;
📐 Evaluating capital adequacy in an insurance deal requires layering several analytical frameworks. At the statutory level, analysts compare projected post-closing [[Definition:Policyholder surplus | policyholder surplus]] against [[Definition:Risk-based capital (RBC) | RBC]] requirements set by the [[Definition:National Association of Insurance Commissioners (NAIC) | NAIC]], identifying how much headroom remains above the company action level and the authorized control level. Rating agency models — from [[Definition:AM Best | AM Best]], S&amp;amp;P, or Moody&amp;#039;s — apply their own [[Definition:Best&amp;#039;s Capital Adequacy Ratio (BCAR) | capital adequacy ratios]], and a downgrade triggered by a capital-depleting acquisition can raise [[Definition:Reinsurance | reinsurance]] costs and erode distribution relationships. Beyond these external benchmarks, internal economic capital models assess whether the combined entity holds enough surplus to absorb stress scenarios relevant to its specific [[Definition:Line of business | lines of business]] and [[Definition:Catastrophe exposure | catastrophe exposures]]. Transaction structuring — the mix of cash, debt, and equity used to fund the deal — directly shapes the post-closing capital position.&lt;br /&gt;
&lt;br /&gt;
💡 Capital adequacy analysis often determines whether an insurance acquisition can proceed at all, or at least in the form originally contemplated. State [[Definition:Department of insurance | insurance regulators]] reviewing [[Definition:Form A (insurance) | Form A]] filings scrutinize the buyer&amp;#039;s pro-forma capital projections and may condition approval on the buyer injecting additional capital, restricting [[Definition:Dividend (insurance) | dividends]] for a specified period, or maintaining minimum surplus levels. For [[Definition:Private equity | private equity]] acquirers, who often use leverage to enhance returns, the tension between capital efficiency and [[Definition:Regulatory risk (M&amp;amp;A) | regulatory capital requirements]] represents a defining constraint on deal structuring. A [[Definition:Solvency opinion | solvency opinion]] frequently accompanies the capital adequacy analysis, providing the board and regulators with independent assurance that the transaction will not compromise the insurer&amp;#039;s financial integrity.&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Related concepts:&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
{{Div col|colwidth=20em}}&lt;br /&gt;
* [[Definition:Risk-based capital (RBC)]]&lt;br /&gt;
* [[Definition:Solvency opinion]]&lt;br /&gt;
* [[Definition:Statutory surplus]]&lt;br /&gt;
* [[Definition:Policyholder surplus]]&lt;br /&gt;
* [[Definition:AM Best]]&lt;br /&gt;
* [[Definition:Regulatory risk (M&amp;amp;A)]]&lt;br /&gt;
{{Div col end}}&lt;/div&gt;</summary>
		<author><name>PlumBot</name></author>
	</entry>
</feed>